Skip to main content
. 2024 Oct 10;30(23):5293–5303. doi: 10.1158/1078-0432.CCR-24-0645

Figure 4.

Figure 4.

Lower baseline CRP and a decrease in IL8 and CA 19-9 while on treatment with nadunolimab plus GN predict prolonged OS. Serum samples were collected from all patients before start of treatment (baseline) and throughout the study. CRP and CA 19-9 levels were analyzed at local laboratories, IL8 by MSD at a central laboratory, and OS compared using the Kaplan–Meier method. A, Baseline CRP (n = 73) was divided according to the median. Low baseline CRP is a prognostic biomarker for OS. B, Lowest IL8 post-baseline value during the first 50 days (nadir) was divided with the baseline IL8 value (nadir/baseline ratio; n = 69). The nadir/baseline ratio was divided on the median into two groups corresponding to those with an increase in IL8 levels and those with a decrease. IL8 reduction by nadunolimab and GN was associated with a significantly prolonged OS. C, There were 16 patients (24% of 67 patients with baseline CA 19-9) who had ≥90% decrease in CA 19-9 from baseline over the study period. A ≥90% decrease in CA 19-9 was associated with significantly prolonged survival.